Jacobsen Malte, Heinemann Lutz
Department of Cardiology, Angiology and Intensive Care Medicine, Medical Faculty, Rheinisch-Westfälische Technische Hochschule Aachen, Aachen, Germany.
Science Consulting in Diabetes GmbH, Düsseldorf, Germany.
J Diabetes Sci Technol. 2025 Jun 10:19322968251347970. doi: 10.1177/19322968251347970.
The performance of laboratory measurements by the people with diabetes (PwD) themselves ("direct-to-consumer testing"; DTCT) is conceptually not new for diabetology. The number of parameters for which such tests are available might increase in the next years, ie, it might go beyond glucose and glycated hemoglobin (HbA). One has to consider several pro and con arguments for DTCT. Appropriate training of the users is a key issue for the meaningful usage of DTCT. Artificial intelligence (AI) might change the way the results of such tests might be used in daily life for the optimization of diabetes therapy. The decision to what extent DTCT will be used will not be made by the health care professional (HCP) but by the PwD themselves. If they see a relevant advantage for themselves in DTCT, this option will become popular.
糖尿病患者（PwD）自行进行实验室检测（“直接面向消费者的检测”；DTCT）在糖尿病学领域从概念上讲并非新鲜事。未来几年，此类检测可用的参数数量可能会增加，也就是说，可能会超出血糖和糖化血红蛋白（HbA）的范围。对于DTCT，必须考虑几个支持和反对的理由。对用户进行适当培训是有意义地使用DTCT的关键问题。人工智能（AI）可能会改变此类检测结果在日常生活中用于优化糖尿病治疗的方式。DTCT的使用程度将不由医疗保健专业人员（HCP）决定，而是由糖尿病患者自己决定。如果他们认为DTCT对自己有相关优势，那么这个选择将会流行起来。
